Lanean...

The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited

BACKGROUND: To compare a near decade of follow-up, newer control cohort data, use of both the societal and third party insurer cost perspectives, and integration of unilateral/bilateral therapy on the comparative effectiveness and cost-effectiveness of intravitreal ranibizumab therapy for neovascula...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Retina Vitreous
Egile Nagusiak: Brown, Gary C., Brown, Melissa M., Lieske, Heidi B., Turpcu, Adam, Rajput, Yamina
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2017
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5304393/
https://ncbi.nlm.nih.gov/pubmed/28289548
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40942-016-0058-3
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!